BERGENBIO ASA (BGBIO.OL) Stock Income Statement
OSL:BGBIO - Euronext Oslo - NO0013251173 - Common Stock - Currency: NOK
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 848.00K | 354.00K | 389.00K | 774.00K | 601.00K | |||
| Operating Expenses | 152.08M | 192.17M | 306.02M | 315.24M | 261.69M | |||
| Research and Development | N/A | N/A | 8.34M | 12.74M | 21.79M | |||
| Selling, General, and Administrative Expenses | 40.60M | 72.89M | 85.48M | 95.61M | 84.33M | |||
| Operating Income | -151.23M | -191.82M | -305.63M | -314.46M | -261.09M | |||
| Interest Income/Expense | 11.95M | 2.48M | 2.63M | 3.08M | 4.39M | |||
| Other Income/Expense | -1.00K | -1.06M | 885.00K | 2.02M | -328.00K | |||
| Income Before Taxes | -139.28M | -190.40M | -302.12M | -309.36M | -257.03M | |||
| Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Income | -139.28M | -190.40M | -302.12M | -309.36M | -257.03M | |||
| EBITDA | -150.78M | -191.60M | -304.75M | -313.15M | -260.37M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.95 | -13.30 | -39.11 | -40.35 | -0.39 | |||
| Non GAAP EPS | -3.75 | N/A | -0.39 | -3.53 | -3.21 | |||
| Statistics | ||||||||
| Profit Margin | -16424.76% | -53785.59% | -77666.32% | -39969.51% | -42766.89% | |||
| Operating Profit Margin | -17834.20% | -54186.16% | -78569.41% | -40628.42% | -43442.76% | |||
All data in NOK